Compare Stocks → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTHNASDAQ:ONCSNASDAQ:PRANNASDAQ:RGLSNASDAQ:SBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$4.22+4.5%$7.00$3.51▼$44.80$2.74M0.6649,897 shs46,084 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsPRANAlterity Therapeutics$2.07+2.5%$1.41$1.09▼$2.91$18.42M1.05130,956 shs68,739 shsRGLSRegulus Therapeutics$2.88$1.71$0.78▼$3.79$58.24M1.459.26 million shs808,981 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path+4.46%-0.24%-17.42%-54.43%-87.37%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-87.57%PRANAlterity Therapeutics+2.48%+16.95%+12.50%-16.87%-23.98%RGLSRegulus Therapeutics0.00%+3.60%+91.36%+125.00%+251.09%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Did you make $29,000 two days with AI options trades? (Ad)What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path1.3686 of 5 stars3.52.00.00.02.30.00.6ONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/APRANAlterity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARGLSRegulus Therapeutics3.035 of 5 stars4.42.00.00.03.12.50.0SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path3.00Buy$40.00847.87% UpsideONCSOncoSec MedicalN/AN/AN/AN/APRANAlterity TherapeuticsN/AN/AN/AN/ARGLSRegulus Therapeutics2.80Moderate Buy$7.25151.74% UpsideSBPHSpring Bank PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest PRAN, BPTH, RGLS, SBPH, and ONCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.003/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/APRANAlterity Therapeutics$150K122.82N/AN/A$1.40 per share1.48RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)ONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/APRANAlterity Therapeutics-$6.40M-$0.70N/A∞N/AN/AN/AN/AN/ARGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)SBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/ALatest PRAN, BPTH, RGLS, SBPH, and ONCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/A3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/APRANAlterity TherapeuticsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A1.601.60ONCSOncoSec MedicalN/A0.890.89PRANAlterity TherapeuticsN/A4.37N/ARGLSRegulus TherapeuticsN/A3.313.31SBPHSpring Bank PharmaceuticalsN/A5.115.11OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%ONCSOncoSec Medical8.69%PRANAlterity Therapeutics3.63%RGLSRegulus Therapeutics92.38%SBPHSpring Bank Pharmaceuticals17.17%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path3.05%ONCSOncoSec Medical1.32%PRANAlterity Therapeutics38.80%RGLSRegulus Therapeutics8.41%SBPHSpring Bank Pharmaceuticals12.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path10680,000658,000OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionablePRANAlterity Therapeutics148.90 millionN/ANot OptionableRGLSRegulus Therapeutics3020.22 million18.52 millionOptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionablePRAN, BPTH, RGLS, SBPH, and ONCS HeadlinesSourceHeadlineWhen will interest rates go down?thetimes.co.uk - January 31 at 12:12 PMBank of Canada expected to 'cautiously' start cutting rates in spring: Deloitte Canadaca.finance.yahoo.com - January 6 at 2:22 PMMan stabbed during street fight in Spring Bank Westhulldailymail.co.uk - September 29 at 8:36 AMWhen is the next Bank Holiday and how many are left in 2023?dailyecho.co.uk - August 13 at 4:35 AMSpring Bank fight involved two feuding families, police believehulldailymail.co.uk - August 8 at 3:14 PMCalls for more police patrols on Spring Bank after fight leaves three in hospitalhulldailymail.co.uk - August 8 at 10:14 AMSpring Bank fight: Six men and a woman held over shocking street violencehulldailymail.co.uk - August 7 at 5:57 AMThe mysterious structure on Spring Bank created to shoot out a beam of lighthulldailymail.co.uk - August 5 at 10:31 AMSyria’s Economic Outlook- Spring 2016worldbank.org - July 23 at 2:47 PMHoliday spending by bank’s customers jumped by 40% annually this springindependent.co.uk - July 17 at 9:22 AMHull's Spring Bank set for major regeneration as plans announced to make it more 'attractive'hulldailymail.co.uk - June 30 at 12:00 PMSpring 2023 Layoff Tracker: Grubhub Cuts 400 Staffforbes.com - June 14 at 8:29 PMRibchester to host 36th annual Spring Bank marketlancashiretelegraph.co.uk - June 7 at 11:53 PMThree big changes for DWP benefit payments including Spring Bank Holidaybirminghammail.co.uk - June 2 at 7:19 PMWhat shops are open this spring bank holiday Monday 2023?metro.co.uk - May 30 at 9:46 AMDWP benefit payment date changes over Spring bank holiday weekendmetro.co.uk - May 28 at 9:06 AMWhen is the the next UK Bank Holiday and how many are left in 2023?uk.news.yahoo.com - May 20 at 4:36 PMWorld Bank, IMF Spring Meetings 2023: What did FMs, central bank governors discuss?moneycontrol.com - April 23 at 3:11 PMThe three bank holidays in May as King's Coronation approachesmanchestereveningnews.co.uk - April 23 at 3:11 PMKing's Coronation bank holiday weekend could get workers 10 days off with just 4 days leavemanchestereveningnews.co.uk - April 21 at 11:06 PMIMF and World Bank Spring Meetings, NRA-ILA Leadership Forum, UN in Libya, and Morecfr.org - April 18 at 9:11 AMWorld Bank, IMF spring meetings get underway in complex economic environmentchannelnewsasia.com - April 18 at 9:11 AMSpring sales 2023: Best deals to shop this Easter bank holidayaol.co.uk - April 10 at 10:13 AMWhen are the bank holidays around the King's coronation?manchestereveningnews.co.uk - April 8 at 10:32 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Alterity TherapeuticsNASDAQ:PRANAlterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Spring Bank PharmaceuticalsNASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.